Diabetes, obesity & metabolism

Risks of complications during and after surgery with glucagon-like peptide-1 receptor drugs

Updated

Abstract

Among 13,361 adults with diabetes, 16.5% were treated with a glucagon-like peptide-1 receptor agonist (GLP1-RA).

  • GLP1-RA users had a lower risk of complications related to decelerated gastric emptying and antiemetic use compared to non-users.
  • No significant differences were observed in the risk of ileus within 7 days, aspiration or pneumonitis, hypoglycaemia, and 30-day mortality between GLP1-RA users and non-users.
  • A sensitivity analysis indicated similar results in patients with both diabetes and obesity.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

DCK is a consultant for Afon, Atropos Health, Better Therapeutics, Glucotrack, Lifecare, Nevro, Novo, and Thirdwayv. SHK reports a relationship with Aligos Therapeutics that includes: consulting or advisory. SHK reports a relationship with GI Dynamics that includes: consulting or advisory. RJG received research support to Emory University for investigator-initiated studies from Novo Nordisk, Dexcom and Eli Lilly and consulting/advisor/honoraria fees from Abbott, Bayer, Dexcom, Eli Lilly, and Novo Nordisk, outside of this work. RJG is partially supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Numbers P30DK111024 (RJG), K23DK123384 (RJG) and R03DK138255-01. JIJ is a founder, equity owner, and consultant to Capillary Biomedical and has received research support. VG and SG work for Atropos Health. DK has received research support from Abbott Diabetes Care. REA and TT have no disclosures.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free